Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Paxil CR "Dear Doctor" Letter Reflects New Labeling On Birth Defects

This article was originally published in The Pink Sheet Daily

Executive Summary

Preliminary results from a retrospective epidemiologic study suggest an increased risk of congenital malformations associated with the use of paroxetine by pregnant women over other antidepressants, the letter states.
Advertisement

Related Content

SSRIs Will Add Fetal Risk Information To Labeling
SSRIs Will Add Fetal Risk Information To Labeling
SSRI/SNRI Pregnancy Exposure Risks Should Be In Patient Labeling, Pediatric Subcmte. Says
SSRI/SNRI Pregnancy Exposure Risks Should Be In Patient Labeling, Pediatric Subcmte. Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS062955

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel